These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 36319063)
1. MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2. Jiang M; Yang Y; Niu L; Li P; Chen Y; Liao P; Wang Y; Zheng J; Chen F; He H; Li H; Chen X J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319063 [TBL] [Abstract][Full Text] [Related]
2. Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity. Chen Y; Jia M; Wang S; Xu S; He N Front Immunol; 2022; 13():835690. PubMed ID: 35251028 [TBL] [Abstract][Full Text] [Related]
3. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models. Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229 [TBL] [Abstract][Full Text] [Related]
4. Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients. Yan F; Du R; Wei F; Zhao H; Yu J; Wang C; Zhan Z; Ding T; Ren X; Chen X; Li H Cancer Immunol Immunother; 2015 Nov; 64(11):1475-85. PubMed ID: 26280204 [TBL] [Abstract][Full Text] [Related]
5. A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer. Jiang M; Liu J; Yang D; Tross D; Li P; Chen F; Alam MM; Faustman DL; Oppenheim JJ; Chen X Int Immunopharmacol; 2021 Dec; 101(Pt A):108345. PubMed ID: 34794079 [TBL] [Abstract][Full Text] [Related]
6. The effects of TNF-α/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer. Qu Y; Wang X; Bai S; Niu L; Zhao G; Yao Y; Li B; Li H Int J Cancer; 2022 Apr; 150(8):1373-1391. PubMed ID: 34766338 [TBL] [Abstract][Full Text] [Related]
7. Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells. Chen X; Hamano R; Subleski JJ; Hurwitz AA; Howard OM; Oppenheim JJ J Immunol; 2010 Jul; 185(1):174-82. PubMed ID: 20525892 [TBL] [Abstract][Full Text] [Related]
8. The Significance of Tumor Necrosis Factor Receptor Type II in CD8 Ye LL; Wei XS; Zhang M; Niu YR; Zhou Q Front Immunol; 2018; 9():583. PubMed ID: 29623079 [TBL] [Abstract][Full Text] [Related]
9. TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4 He T; Chen Y; Yang D; Islam MS; Chou CK; Liu J; Faustman DL; Oppenheim JJ; Chen X Cell Oncol (Dordr); 2023 Feb; 46(1):167-177. PubMed ID: 36369606 [TBL] [Abstract][Full Text] [Related]
10. Scutellarin enhances anti-tumor immune responses by reducing TNFR2-expressing CD4 Chen S; Li R; Chen Y; Chou CK; Zhang Z; Yang Y; Liao P; Wang Q; Chen X Biomed Pharmacother; 2022 Jul; 151():113187. PubMed ID: 35676787 [TBL] [Abstract][Full Text] [Related]
11. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. Chen X; Subleski JJ; Kopf H; Howard OM; Männel DN; Oppenheim JJ J Immunol; 2008 May; 180(10):6467-71. PubMed ID: 18453563 [TBL] [Abstract][Full Text] [Related]
12. TNFR2 deficiency impairs the growth of mouse colon cancer. Li P; Yang Y; Yang X; Wang Y; Chou CK; Jiang M; Zheng J; Chen F; Chen X Int J Biol Sci; 2023; 19(4):1024-1035. PubMed ID: 36923938 [No Abstract] [Full Text] [Related]
13. Regulatory T cells express Tumor Necrosis Factor Receptor 2 with the highest intensity among CD4 Ghods A; Mehdipour F; Shariat M; Talei AR; Ghaderi A Mol Immunol; 2021 Sep; 137():52-56. PubMed ID: 34214829 [TBL] [Abstract][Full Text] [Related]
14. Aberrant frequency of TNFR2-expressing CD4+ FoxP3+ regulatory T cells in nasopharyngeal carcinoma patients. Engku Abd Rahman ENS; Irekeola AA; Shueb RH; Mat Lazim N; Mohamud R; Chen X; Ghazali L; Awang NMSH; Haron A; Chan YY Cytokine; 2023 Oct; 170():156341. PubMed ID: 37657236 [TBL] [Abstract][Full Text] [Related]
15. TNFR2-expressing CD4 He J; Li R; Chen Y; Hu Y; Chen X Prog Mol Biol Transl Sci; 2019; 164():101-117. PubMed ID: 31383403 [TBL] [Abstract][Full Text] [Related]
16. Anti-TNFR2 Antibody-Conjugated PLGA Nanoparticles for Targeted Delivery of Adriamycin in Mouse Colon Cancer. Li P; Yang Y; Wang Y; Zheng J; Chen F; Jiang M; Chou CK; Cong W; Li Z; Chen X Research (Wash D C); 2024; 7():0444. PubMed ID: 39247806 [TBL] [Abstract][Full Text] [Related]
17. Accumulation of TNFR2-expressing regulatory T cells in malignant pleural effusion of lung cancer patients is associated with poor prognosis. Ye LL; Peng WB; Niu YR; Xiang X; Wei XS; Wang ZH; Wang X; Zhang SY; Chen X; Zhou Q Ann Transl Med; 2020 Dec; 8(24):1647. PubMed ID: 33490159 [TBL] [Abstract][Full Text] [Related]
18. TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments. Liao P; Jiang M; Islam MS; Wang Y; Chen X Front Immunol; 2023; 14():1097090. PubMed ID: 36865537 [TBL] [Abstract][Full Text] [Related]
19. Signaling pathway(s) of TNFR2 required for the immunoregulatory effect of CD4 He T; Zhao Y; Zhao P; Zhao L; Zakaria J; Wang K Int Immunopharmacol; 2022 Jul; 108():108823. PubMed ID: 35623290 [TBL] [Abstract][Full Text] [Related]
20. Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer. Nie Y; He J; Shirota H; Trivett AL; Yang D; Klinman DM; Oppenheim JJ; Chen X Sci Signal; 2018 Jan; 11(511):. PubMed ID: 29295954 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]